Resolution of FCA Case for Global Healthcare Company

We represented a global healthcare company in relation to an investigation conducted by DOJ and HHS-OIG into alleged violations of the False Claims Act. The alleged false claims involved the manner in which certain negative pressure wound therapy devices were being marketed and distributed as durable medical equipment. Conducted an internal investigation and negotiated a favorable settlement with DOJ, HHS-OIG, and counsel for the relator. No post-settlement oversight was required.

You Also May Be Interested In:

  • Representation of Life Sciences Company Fagron Holding USA LLC

    We served as lead counsel representing a national pharmaceutical ingredient supplier and its wholly-owned subsidiaries in an investigation of alleged...
    Client Type: Private Company
  • We served as counsel to two hospitals in a qui tam lawsuit alleging that a cardiologist (Dr. Korban) billed Medicare...
    Client Type: Public Company
  • We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.

     

    We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc.,...
    Client Type: Public Company